1609392-27-9Relevant articles and documents
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Wrobleski, Stephen T.,Moslin, Ryan,Lin, Shuqun,Zhang, Yanlei,Spergel, Steven,Kempson, James,Tokarski, John S.,Strnad, Joann,Zupa-Fernandez, Adriana,Cheng, Lihong,Shuster, David,Gillooly, Kathleen,Yang, Xiaoxia,Heimrich, Elizabeth,McIntyre, Kim W.,Chaudhry, Charu,Khan, Javed,Ruzanov, Max,Tredup, Jeffrey,Mulligan, Dawn,Xie, Dianlin,Sun, Huadong,Huang, Christine,D'Arienzo, Celia,Aranibar, Nelly,Chiney, Manoj,Chimalakonda, Anjaneya,Pitts, William J.,Lombardo, Louis,Carter, Percy H.,Burke, James R.,Weinstein, David S.
, p. 8973 - 8995 (2019/11/14)
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formi
PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE
-
, (2018/10/25)
The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.